MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by BRAUN, S.
Right arrow Articles by LEVITZKI, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BRAUN, S.
Right arrow Articles by LEVITZKI, A.

Molecular Pharmacology, Vol 16, 737-748, Copyright © 1979 by the American Society for Pharmacology and Experimental Therapeutics

The Attenuation of Epinephrine-Dependent Adenylate Cyclase by Adenosine and the Characteristics of the Adenosine Stimulatory and Inhibitory Sites

SERGEI BRAUN 1 and ALEXANDER LEVITZKI 1

1 Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel

Turkey erythrocyte and rat caudate adenylate cyclase [ATP pyrophosphatase-lyase (cyclizing) EC 4.6.1.1] respond to beta-receptor adenergic agents and to adenosine agonists. In both systems single adenylate cyclase responds to the two receptors. In both tissues the effect of the two agonists is not additive and the enzyme can be activated only by one agonist at a time.

The adenosine receptor is permanently coupled to the adenylate cyclase moiety and therefore the portion of the enzyme that is in its active form is directly proportional to the degree of saturation of adenosine sites. In contrast, the beta-receptor is not coupled to the enzyme and activates the latter by a biomolecular collision between the two species that occurs during the diffusion of the hormone bound beta-receptor. It follows that increasing concentrations of adenosine strongly enlarge the part of cyclase molecules governed by the adenosine receptor and, accordingly, reduce the free enzyme pool, accessible to beta-receptor agonists, whereas hormone-occupied beta-receptor cannot influence the pool of adenylate cyclase accessible to the adenosine receptor. Hence at saturating concentrations of adenosine only the adenosine-induced activity will be expressed and the combined effect of the two ligands is independent of beta-agonist concentration. In turkey erythrocyte adenylate cyclase adenosine is a much poorer agonist than a beta-agonist. Therefore, increasing adenosine concentrations inhibit beta-agonist-stimulated cAMP production. The caudate nucleus adenylate cyclase presents a diametrically opposite situation where adenosine is a more potent agonist than epinephrine and thus, in the presence of adenosine, cAMP production is increased above that achieved by beta-agonists. Caudate nucleus cyclase but not turkey erythrocyte cyclase possesses also an adenosine inhibitory site distinct from the stimulatory site. The ligand specificities of these two types of adenosine sites are different. The possible physiological role of the adenosine-induced modulation of hormonal response is discussed.

Submitted on December 19, 1978
Accepted on May 24, 1979




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C. Charalambous, I. Gsandtner, S. Keuerleber, L. Milan-Lobo, O. Kudlacek, M. Freissmuth, and J. Zezula
Restricted Collision Coupling of the A2A Receptor Revisited: EVIDENCE FOR PHYSICAL SEPARATION OF TWO SIGNALING CASCADES
J. Biol. Chem., April 4, 2008; 283(14): 9276 - 9288.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1979 by the American Society for Pharmacology and Experimental Therapeutics